All News

RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Jack Cush, MD

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.

Read Article
ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Jack Cush, MD

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Read Article
LBP.red_.jpg

Upadacitinib in non-radiographic Axial Spondyloarthritis

Jack Cush, MD

The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.

Read Article
2021,year

ICYMI: 2021 Rheumatology Year in Review

Jack Cush, MD

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations

Jack Cush, MD

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail psoriasis; with new PsA related domains uveitis and inflammatory bowel disease.

Read Article
Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY

Links:

Dr. John Cush RheumNow ( View Tweet)
Record a Question or Comment... Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/ZJsR0R5WNW https://t.co/2GU5aaSwDZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/5upWNItwGy https://t.co/RMwDYVubOk

Links:

Dr. John Cush RheumNow ( View Tweet)
The 2022 ACR abstracts are published and posted for you. Let the Learning begin! https://t.co/ZqMAc8jV3U https://t.co/3iCGnzsPI5

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/1aSrRsLkel https://t.co/gmh155ty6w

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU

Links:

Dr. John Cush RheumNow ( View Tweet)
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/QUTIbK3r89 https://t.co/FZcTLREida

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi

Links:

Dr. John Cush RheumNow ( View Tweet)
Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/uMY5uPPabA https://t.co/nG2RO6oEJQ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA approved Abbvies risakizumab-rzaa (Skyrizi) as the 1st interleukin-23 inhibitor for use in adults with moderately to severely active Crohn's disease (600 mg IV at wk 0, 4, 8, &q8wk @ 360 mg SC). Approval based on ADVANCE, MOTIVATE & FORTIFY RCTs https://t.co/OMYNB1yr2R https://t.co/QMn9GWlYm9

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment of pyoderma gangrenosum is clinically empiric. Full read ref w/ Graded Rx Recommendations: - 1st line: Steriods or Cyclosporin - Consider biologics: TNFi, IL-1, IL-12/23, IL-17, IL-23 - Others: MTX, MMF, AZA, Dap, colchic, thalidomide, IVIG https://t.co/uMJyfFzsRB https://t.co/vw4VqbjZWh

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×